Cathie Wood's ARK buys Bullish stock, sells Shopify and Guardant Health

Cathie Wood's ARK ETFs executed significant portfolio adjustments on August 13, 2025, demonstrating a strong bullish stance on digital assets and continued conviction in the genomics and genetic diagnostics sectors. ARK notably invested $93.7 million into cryptocurrency exchange platform Bullish and accumulated shares in CareDx, GeneDx, and Personalis. Concurrently, ARK strategically reduced exposure to precision oncology firm Guardant Health, healthcare technology company 908 Devices, and e-commerce giant Shopify, indicating a re-evaluation of prospects in these areas and an active capital reallocation strategy.

Analysis

On August 13, 2025, ARK Invest executed a significant portfolio rebalancing, underscoring a high-conviction pivot towards digital assets and a strategic refinement within its healthcare holdings. The firm's most notable move was a substantial $93.7 million investment in cryptocurrency exchange platform Bullish (BLSH) across its ARKK, ARKW, and ARKF ETFs, a decisive bet on the digital asset infrastructure coinciding with reports of record Bitcoin prices. Concurrently, ARK reinforced its bullish stance on the genomics and diagnostics sector, accumulating shares in CareDx (CDNA), GeneDx (WGS), and continuing a week-long buying streak in Personalis (PSNL). This targeted buying contrasts sharply with strategic divestments from other technology names. ARK trimmed its exposure to e-commerce, selling over $3.1 million worth of Shopify (SHOP) shares, which continues a recent trend of reducing its position in the company. Within healthcare, the firm offloaded $1.4 million of Guardant Health (GH) and over $600,000 of 908 Devices (MASS), suggesting a specific capital rotation out of precision oncology and certain healthcare technology segments and into genomics and diagnostics.

Key Decisions for Investors

• Given the substantial $93.7 million capital allocation to Bullish (BLSH), investors should consider this a high-conviction signal on the crypto-exchange sector, potentially warranting a closer look at BLSH as a key institutional play.
• ARK's consistent selling of Shopify (SHOP), including the latest $3.1 million divestment, indicates weakening conviction and constitutes a bearish signal; current SHOP holders may want to reassess their thesis for the stock.
• The simultaneous sale of Guardant Health (GH) and purchase of CareDx (CDNA), GeneDx (WGS), and Personalis (PSNL) signals a clear sub-sector rotation within biotech, favoring diagnostics and genomic sequencing over precision oncology at this time.
• Investors tracking ARK's portfolio should recognize these trades as evidence of an active and high-turnover strategy, implying that positions can change rapidly and should be monitored closely for signs of shifting conviction.